Antiplatelet Therapy Clinical Trials

10 recruitingLast updated: May 29, 2026

There are 10 actively recruiting antiplatelet therapy clinical trials across 10 countries. Studies span Not Applicable, Phase 4, Phase 3. Top locations include Wŏnju, Gangwon State, South Korea, Lugano, Ch/ti, Switzerland, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Antiplatelet Therapy Trials at a Glance

10 actively recruiting trials for antiplatelet therapy are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Wŏnju, Lugano, and Beijing. Lead sponsors running antiplatelet therapy studies include Cardiocentro Ticino, Genoss Co., Ltd., and Fondazione Ricerca e Innovazione Cardiovascolare ETS.

Browse antiplatelet therapy trials by phase

Treatments under study

About Antiplatelet Therapy Clinical Trials

Looking for clinical trials for Antiplatelet Therapy? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Antiplatelet Therapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Antiplatelet Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Coronary Artery DiseasePercutaneous Coronary InterventionAcute Coronary Syndromes+3 more
Cardiocentro Ticino355 enrolled1 locationNCT07582835
Recruiting

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

Coronary Artery DiseaseAntiplatelet TherapyMinimally Invasive Coronary Revascularization Surgery
Cardiocentro Ticino30 enrolled1 locationNCT07514962
Recruiting
Not Applicable

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Disease+22 more
Fondazione Ricerca e Innovazione Cardiovascolare ETS576 enrolled1 locationNCT06535568
Recruiting
Phase 4

Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

Dual Antiplatelet TherapyST Elevated Myocardial Infarction
Research Maatschap Cardiologen Rotterdam Zuid1,656 enrolled26 locationsNCT05491200
Recruiting
Not Applicable

Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

Coronary Artery DiseaseCoronary Artery Bypass GraftingSaphenous Vein+1 more
Kexiang Liu, MD300 enrolled1 locationNCT06981390
Recruiting
Not Applicable

24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

Coronary Artery DiseaseDrug-eluting StentDual Antiplatelet Therapy+1 more
China National Center for Cardiovascular Diseases3,300 enrolled1 locationNCT06014060
Recruiting
Phase 4

Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)

Antiplatelet TherapyHemorrhagic Infarction
Second Affiliated Hospital, School of Medicine, Zhejiang University294 enrolled1 locationNCT04624295
Recruiting

Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

Coronary Artery DiseasePercutaneous Coronary InterventionDual Antiplatelet Therapy
Genoss Co., Ltd.1,000 enrolled1 locationNCT06075433
Recruiting

Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease

Percutaneous Coronary InterventionDual Antiplatelet Therapy
Genoss Co., Ltd.1,000 enrolled1 locationNCT06075420
Recruiting
Phase 4

Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial

AspirinAortic StenosisTAVI(Transcatheter Aortic Valve Implantation)+2 more
OCEAN-SHD Study Group400 enrolled1 locationNCT06007222